Bile Duct Cancer (Cholangiocarcinoma) Treatment Market: By Therapy Type (Drug Therapy (Gemcitabine Combination Therapy,5-fluorouracil Combination Therapy, Capecitabine Combination Therapy and Gemcitabine Alone) Radiation Therapy (Brachytherapy and External Beam Radiation Therapy (EBRT), and Surgery), By Disease Indication (Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer (Perihilar Bile Duct Cancer and Distal Extrahepatic Bile Duct Cancer)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography 

Purchase Option

$ 4400
$ 6600
$ 8900

Bile Duct Cancer Treatment Market size was valued at USD 371.6 million in 2022 and is anticipated to grow at a CAGR of 9.6 % over 2023-2029. Bile duct cancer, also known as cholangiocarcinoma, refers to a type of cancer that originates in the bile ducts, which are the tubes that carry bile from the liver to the small intestine. Bile duct cancer can occur in different parts of the bile duct system, including the intrahepatic bile ducts (inside the liver), the perihilar bile ducts (where the ducts exit the liver), and the distal bile ducts (closer to the small intestine). Treatment for bile duct cancer is determined based on the stage of the cancer, its location, the patient's overall health, and other individual factors.

The increasing incidence of bile duct cancer (cholangiocarcinoma) and the growing awareness of this disease are pivotal drivers propelling the growth of the bile duct cancer treatment market. As per the American Cancer Society, every year in the United States, around 8,000 people are diagnosed with Bile duct cancer. As the prevalence of cholangiocarcinoma rises, there is a heightened demand for effective treatment options to address this challenging condition. Simultaneously, greater awareness among healthcare providers, patients, and the general population has led to earlier detection and diagnosis, enabling timely intervention. This increased recognition of cholangiocarcinoma's significance has spurred research efforts and the development of innovative treatment modalities, including targeted therapies, surgical advancements, and personalized medicine approaches.

Moreover, advancements in medical science play a pivotal role in driving the revenues of the cholangiocarcinoma treatment market. As our understanding of the molecular and genetic intricacies of cholangiocarcinoma deepens, novel avenues for targeted therapies and personalized treatment strategies emerge. These advancements enable healthcare professionals to develop more precise and effective interventions tailored to the specific characteristics of each patient's tumor. However, the complexity, heterogeneity, and limited understanding of the disease's underlying mechanisms can pose challenges in developing effective treatment options. Meanwhile, recent advancements in immunotherapy, particularly immune checkpoint inhibitors, hold promise for revolutionizing cancer treatment outcomes and expanding the market. Furthermore, key market players are developing innovative solutions to treat cholangiocarcinoma. For example, in September 2022, Taiho Oncology, Inc. announced the U.S. Food and Drug Administration (FDA) approval of LYTGOBI tablets for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA).

Bile Duct Cancer Treatment Market Key Developments:  

  • In September 2022, AstraZeneca announced the approval of Imfinzi (durvalumab) in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).
  • In April 2020, Incyte announced the approval of the Pemigatinib for treatment of certain adults with previously treated unresectable cholangiocarcinoma.

Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

9.6%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Dynamics

The industrialization in developing counters such as India, China, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among the industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market. For instance, in 2017 RedHill Bio received orphan drug designation for YELIVA (ABC294640) in the treatment of cholangiocarcinoma.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Segmentation

By Therapy Type
  • Drug Therapy
    • Gemcitabine Combination Therapy
    • 5-fluorouracil Combination Therapy
    • Capecitabine Combination Therapy
    • Gemcitabine Alone
  • Radiation Therapy
    • Brachytherapy
    • External Beam Radiation Therapy (EBRT)
  • Surgery
By Disease Indication
  • Intrahepatic Bile Duct Cancer
  • Extrahepatic Bile Duct Cancer
    • Perihilar Bile Duct Cancer
    • Distal Extrahepatic Bile Duct Cancer
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The bile duct cancer (cholangiocarcinoma) treatment market size was valued at USD 371.6 million in 2022.

The increasing incidence of cholangiocarcinoma and increased research and development activities are some of the key opportunities for companies to enhance their revenue over the forecast years.

The bile duct cancer (cholangiocarcinoma) treatment market key players Abbott Laboratories (U.S.), Apotex Inc. (Canada), AstraZeneca (U.K), Reddy's Laboratories Ltd. (India), GlaxoSmithKline plc (U.K), Mylan N.V. (U.S.), Pfizer Inc. (U.S), Novartis AG (Switzerland), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd (Israel), Valeant Pharmaceuticals International, Inc. (Canada)

Continual research and development aimed at incorporating data analytics and machine learning to provide personalized treatment and advancements in surgical techniques stand out as a significant trend within the bile duct cancer (cholangiocarcinoma) treatment market.

1.Executive Summary
2.Global Bile Duct Cancer Treatment Market Introduction 
2.1.Global Bile Duct Cancer Treatment Market  - Taxonomy
2.2.Global Bile Duct Cancer Treatment Market  - Definitions
2.2.1.Therapy Type
2.2.2.Disease Indication
2.2.3.Distribution Channel
2.2.4.Region
3.Global Bile Duct Cancer Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Bile Duct Cancer Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Bile Duct Cancer Treatment Market  By Therapy Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Drug Therapy
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Radiation Therapy
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Surgery
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Bile Duct Cancer Treatment Market  By Disease Indication, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Intrahepatic Bile Duct Cancer
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Extrahepatic Bile Duct Cancer
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Bile Duct Cancer Treatment Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Bile Duct Cancer Treatment Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Bile Duct Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Therapy Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Drug Therapy
9.1.2.Radiation Therapy
9.1.3.Surgery
9.2.  Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Intrahepatic Bile Duct Cancer
9.2.2.Extrahepatic Bile Duct Cancer
9.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Bile Duct Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Therapy Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Drug Therapy
10.1.2.Radiation Therapy
10.1.3.Surgery
10.2.  Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Intrahepatic Bile Duct Cancer
10.2.2.Extrahepatic Bile Duct Cancer
10.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11.Asia Pacific (APAC) Bile Duct Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Therapy Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Drug Therapy
11.1.2.Radiation Therapy
11.1.3.Surgery
11.2.  Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Intrahepatic Bile Duct Cancer
11.2.2.Extrahepatic Bile Duct Cancer
11.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Bile Duct Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Therapy Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Drug Therapy
12.1.2.Radiation Therapy
12.1.3.Surgery
12.2.  Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Intrahepatic Bile Duct Cancer
12.2.2.Extrahepatic Bile Duct Cancer
12.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Bile Duct Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Therapy Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Drug Therapy
13.1.2.Radiation Therapy
13.1.3.Surgery
13.2.  Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Intrahepatic Bile Duct Cancer
13.2.2.Extrahepatic Bile Duct Cancer
13.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Abbott Laboratories (U.S.)
14.2.2.Apotex Inc. (Canada)
14.2.3.AstraZeneca (U.K)
14.2.4.Reddy's Laboratories Ltd. (India)
14.2.5.GlaxoSmithKline plc (U.K)
14.2.6.Mylan N.V. (U.S.)
14.2.7.Pfizer Inc. (U.S)
14.2.8.Novartis AG (Switzerland)
14.2.9.Sanofi (France)
14.2.10.Sun Pharmaceutical Industries Ltd. (India)
14.2.11.Teva Pharmaceutical Industries Ltd (Israel)
14.2.12.Valeant Pharmaceuticals International, Inc. (Canada)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Abbott Laboratories (U.S.)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K)
  • Reddy's Laboratories Ltd. (India)
  • GlaxoSmithKline plc (U.K)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (U.S)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Valeant Pharmaceuticals International, Inc. (Canada)

Adjacent Markets